New cholesterol drugs enter human testing for first time

NCT ID NCT07691268

Completed Disease control Sponsor: Korea United Pharm. Inc. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This early-stage trial tests two experimental drugs, UI111 and UIC202006, in healthy adult volunteers. The goal is to check the drugs' safety and how the body processes them after a single dose taken with food. The study uses a crossover design, meaning each participant receives both drugs at different times. Results will help decide whether to move forward with larger studies in people with high cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UI111 and UIC202006 (experimental drugs for dyslipidemia)
What this could lead to: If successful, this could lead to a new treatment option for managing high cholesterol and fats in the blood (dyslipidemia).
What could go wrong: This is a very early Phase 1 study in healthy volunteers, so it does not yet test if the drugs actually work for dyslipidemia. The drugs may cause side effects or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA

Contacts and locations

Show contact details

Locations

H plus Yangji Hospital

Seoul, Gwanak-gu 08779, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.